This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aggarwal, S. Articles by Denmeade, S. R. Search for Related Content PubMed PubMed Citation Articles by Aggarwal, S. Articles by Denmeade, S. R.

A Dimeric Peptide That Binds Selectively to Prostate-Specific Membrane Antigen and Inhibits its Enzymatic Activity

¹ The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine and ² Chemical and Biomolecular Engineering Department, The Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland

Requests for reprints: Samuel R. Denmeade, Department of Oncology, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-502-3941; Fax: 410-614-8397; E-mail: denmesa{at}jhmi.edu.

Prostate-specific membrane antigen (PSMA) is highly expressed by both normal and malignant prostate epithelial cells and by the neovasculature of many tumor types; however, it is not expressed by normal endothelial cells or other normal tissues. PSMA, therefore, represents an attractive candidate for selectively targeted therapies for prostate and/or other solid tumors. As an alternative approach to antibody-based anti-PSMA therapies, small peptides that bind selectively to PSMA-producing cells can be used to deliver cytotoxic drugs, protein toxins, and viruses selectively to malignant sites while minimizing systemic toxicity to normal tissues. Small peptides are relatively inexpensive to produce, not immunogenic, and easily coupled to cytotoxic agents. In the present study, a random phage library consisting of linear 12 amino acid peptides was used to identify peptides that bound selectively to PSMA. From a series of monomeric peptides, one with the sequence WQPDTAHHWATL was used to show binding of soluble peptide to PSMA. A dimeric version of this peptide showed markedly enhanced binding to soluble PSMA and an IC₅₀ of 2.2 µmol/L for inhibition of PSMA enzymatic activity. Fluorescently labeled dimeric peptide bound selectively to PSMA-producing prostate cancer cells in vitro with no significant binding to non–PSMA-producing cells. Molecular modeling of the dimeric peptide revealed that histidine residues in close vicinity can efficiently coordinate a divalent ion and hold the peptide in a favorable configuration for binding and subsequent inhibition. These dimeric peptides, therefore, represent putative PSMA-selective targeting agents that are currently being evaluated for selective binding in vivo. (Cancer Res 2006; 66(18): 9171-7)

This article has been cited by other articles:

				A. M. LeBeau, W. N. Brennen, S. Aggarwal, and S. R. Denmeade Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin Mol. Cancer Ther., May 1, 2009; 8(5): 1378 - 1386. [Abstract] [Full Text] [PDF]